Skip to content
Middletown Life
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 4, 2026
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 6, 2026
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
1
2
Next Page
→